Expert Interview
A second look: Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM)
Ticker(s): ALNY, BBIO, PFEInstitution: Stanford
- Cardiologist and Instructor at Stanford University School of Medicine.
- Manages patients at the amyloid center at Stanford and directs the amyloid clinic at the Palo Alto VA.
- Research focuses on Investigating the molecular mechanisms behind genetic risk factors for human cardiovascular disease focusing on amyloidosis, cardio-oncology, and atherosclerotic diseases.
How do you view Attruby compared to Vyndaqel?
Added By: wilson_adminHow do you view Amvuttra versus the oral options?
Added By: wilson_adminWhat are your thoughts on some of the investigational therapies, i.e. eplontersen and Nex-Z
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
